IgA antibodies

Over the past few decades, monoclonal antibodies have become some of the most successful biologic drugs, transforming the treatment of hematologic malignancies, solid tumors, autoimmune disorders, and infectious diseases. While IgG antibodies remain the dominant format in approved cancer therapies, growing attention is turning toward non-IgG antibodies—notably IgA, IgE, and IgY—for their distinct biological properties …

>>>